Cd71 binding fibronectin type iii domains
AssigneeARO Biotherapeutics Company
InventorsRussell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin
Life of this patent
Estimating the term…
Abstract
The present disclosure related to polypeptide, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Claims17
-52. (canceled)
A method of delivering a polynucleotide to a muscle cell, wherein the method comprises contacting the muscle cell with the polynucleotide conjugated to a polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NO:
- 96, 115, 152, 168, 174, 175, 177, 190, 192, 207, 252, 263, 284, 296, 300, 303, or 307.
Dependencies are inferred from the claim text.